- Home
- TXMD vs GNTA Comparison
TXMD vs GNTA Comparison
Compare TXMD & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXMD | GNTA |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | Italy |
| Employees | N/A | 13 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 19.9M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | TXMD | GNTA |
|---|---|---|
| Price | $1.98 | $0.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.6K | ★ 44.5K |
| Earning Date | 05-12-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.68 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,761,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 35.25 | N/A |
| 52 Week Low | $0.98 | $0.59 |
| 52 Week High | $2.95 | $10.00 |
Technical Indicators
Market Signals| Indicator | TXMD | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 39.25 | 39.30 |
| Support Level | $1.94 | $0.61 |
| Resistance Level | $2.05 | $0.76 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 12.50 | 21.01 |
Price Performance
Historical ComparisonAbout TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.